- Home
- NTIP vs LPCN Comparison
NTIP vs LPCN Comparison
Compare NTIP & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- LPCN
- Stock Information
- Founded
- NTIP 1990
- LPCN 1997
- Country
- NTIP United States
- LPCN United States
- Employees
- NTIP N/A
- LPCN N/A
- Industry
- NTIP Multi-Sector Companies
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- LPCN Health Care
- Exchange
- NTIP Nasdaq
- LPCN Nasdaq
- Market Cap
- NTIP 32.9M
- LPCN 27.1M
- IPO Year
- NTIP 1998
- LPCN N/A
- Fundamental
- Price
- NTIP $1.38
- LPCN $4.37
- Analyst Decision
- NTIP
- LPCN Strong Buy
- Analyst Count
- NTIP 0
- LPCN 1
- Target Price
- NTIP N/A
- LPCN $10.00
- AVG Volume (30 Days)
- NTIP 62.9K
- LPCN 34.0K
- Earning Date
- NTIP 03-07-2025
- LPCN 03-06-2025
- Dividend Yield
- NTIP 7.25%
- LPCN N/A
- EPS Growth
- NTIP N/A
- LPCN N/A
- EPS
- NTIP N/A
- LPCN N/A
- Revenue
- NTIP $1,881,000.00
- LPCN $7,922,926.00
- Revenue This Year
- NTIP N/A
- LPCN N/A
- Revenue Next Year
- NTIP N/A
- LPCN N/A
- P/E Ratio
- NTIP N/A
- LPCN N/A
- Revenue Growth
- NTIP 129.39
- LPCN N/A
- 52 Week Low
- NTIP $1.22
- LPCN $3.20
- 52 Week High
- NTIP $2.25
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- NTIP 51.53
- LPCN 38.51
- Support Level
- NTIP $1.33
- LPCN $4.48
- Resistance Level
- NTIP $1.47
- LPCN $4.89
- Average True Range (ATR)
- NTIP 0.07
- LPCN 0.35
- MACD
- NTIP -0.00
- LPCN -0.06
- Stochastic Oscillator
- NTIP 43.75
- LPCN 9.60
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.